REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal.
Bioorg Med Chem. 2011 Nov 15;19(22):6853-9. doi: 10.1016/j.bmc.2011.09.032. Epub 2011 Sep 22.
Potent and selective ligands with a nucleoside skeleton are generally thought as agonists of the human A(3) adenosine receptor (AR), however, some of them can also act as full antagonists. This work reports a Quantitative Structure-Activity Relationship (QSAR) study for predicting the binding affinity of such type of compounds towards the A(3) AR. Several different theoretical molecular descriptors, calculated only on the basis of knowledge of the molecular structure and an efficient variable selection procedure, such as forward stepwise regression, led to models with satisfactory accuracy and predictive ability. But the best-final QSAR model is based on the Molecule Representation of Structures based on Electron diffraction (3D-MoRSE) descriptors capturing a reasonable interpretation. This QSAR model is able to explain more than 85% of the variance in the experimental affinity and manifests good predictive ability as indicated by the higher Q(2)s of cross- and external-validations. The model obtained in this study may provide guidance for future design of new potent and selective human A(3) AR full antagonists with a nucleoside skeleton.
具有核苷骨架的有效且选择性配体通常被认为是人类 A(3) 腺苷受体 (AR) 的激动剂,但其中一些也可以作为完全拮抗剂。本工作报道了一种定量构效关系 (QSAR) 研究,用于预测此类化合物与 A(3) AR 的结合亲和力。仅基于分子结构知识和有效的变量选择过程(如逐步正向回归)计算的几种不同的理论分子描述符,可得到具有令人满意的准确性和预测能力的模型。但最佳最终 QSAR 模型是基于电子衍射的基于分子结构的分子表示(3D-MoRSE)描述符,可进行合理的解释。该 QSAR 模型能够解释实验亲和力中超过 85%的变化,并且通过交叉验证和外部验证的更高 Q(2) 值表明具有良好的预测能力。本研究中获得的模型可能为未来设计具有核苷骨架的新型有效且选择性的人类 A(3) AR 全拮抗剂提供指导。